Molecular Partners AG (MOLN.SW)
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
3.36+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+10.2%
The outlook
Molecular Partners AG currently reads as leaning bullish based on buy — 2.0 avg of 2 analysts, above its 50- & 200-day averages, 54% of the way from its 52-week low to high, avg target +168% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 2 analysts
Price trendAbove its 50- & 200-day averages
52-week range54% of the way from its 52-week low to high
Price targetAvg target +168% vs current price
Analyst price target
~12-month · 2 analysts9.00average target+167.9% vs now
Now 3.36
Low 3.00High 15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$126.0M
52-wk high
3.96
52-wk low
2.66
50-day avg
3.14
200-day avg
3.28
Trailing P/E
—